Bevacizumab
As of the edition of 20 October 2026, Bevacizumab is an antibody: marketed, first approved in 2004 (US); acts on VEGFA; US protection ends in 2027.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2007
- Kind
- Antibody
- Brand name
- Avastin
- First approved
- 26 February 2004 (US)
- Approvals on record
- 22 in 5 regions
- Holder of the most recent approval
- Outlook Therapeutics; 10 holders in all
- Withdrawn from market
- 21 June 2021 (in some regions)
- Registered trials
- 2,344, 355 stopped early
- Disease areas
- Cancer; Digestive system; Urinary and reproductive; Pregnancy and women's health; Hormones; Lungs and airways
US protection
US protection ends in 2027.
The orphan exclusivity ends in 2027 (it covers one use only). The application that gives this date is held by Roche.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product2 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 2 listings behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
2 companies on route B because of this drug.
Companies on route B for this drug
In the product2 companies are on route B because of Bevacizumab.
See the 2 companies on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| VEGFA | Vascular endothelial growth factor A, long form | P15692 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 176 | 84 | 30 | 17 |
| Phase 1 | 340 | 199 | 72 | 52 |
| Phase 2 | 1,442 | 679 | 337 | 230 |
| Phase 3 | 335 | 159 | 100 | 45 |
| Phase 4 | 51 | 27 | 6 | 11 |
| All trials | 2,344 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Roche | Applicant and Lead sponsor of trials | 1998 to now |
| Pfizer | Later holder and Lead sponsor of trials | 2003 to now |
| Amgen | Later holder and Lead sponsor of trials | 2005 to now |
| Outlook Therapeutics | Later holder and Lead sponsor of trials | 2018 to now |
| Nippon Kayaku | Later holder | 2022 to now |
| Outlook Therapeutics NL B. V | Later holder | 2024 to now |